[{"orgOrder":0,"company":"EyeBio","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"EYE103","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"EyeBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyeBio \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"EyeBio \/ Merck & Co"},{"orgOrder":0,"company":"EyeBio","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2023","type":"Series A Financing","leadProduct":"EYE103","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"EyeBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyeBio \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"EyeBio \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"EyeBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"EYE103","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"EyeBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyeBio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"EyeBio \/ Inapplicable"},{"orgOrder":0,"company":"EyeBio","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"EYE103","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"EyeBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyeBio \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"EyeBio \/ Merck & Co"}]

Find Clinical Drug Pipeline Developments & Deals by EyeBio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Cophex
                          Not Confirmed
                          Cophex
                          Not Confirmed

                          Details : The acquisition includes Restoret (EYE103), a first-in-class tetravalent, tri-specific antibody and late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration.

                          Product Name : Restoret

                          Product Type : Other Large Molecule

                          Upfront Cash : $1,300.0 million

                          December 07, 2024

                          Lead Product(s) : EYE103

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase I

                          Sponsor : Merck & Co

                          Deal Size : $3,000.0 million

                          Deal Type : Acquisition

                          blank

                          02

                          Cophex
                          Not Confirmed
                          Cophex
                          Not Confirmed

                          Details : The acquisition includes Restoret (EYE103), a first-in-class tetravalent, tri-specific antibody and late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration.

                          Product Name : Restoret

                          Product Type : Other Large Molecule

                          Upfront Cash : $1,300.0 million

                          May 29, 2024

                          Lead Product(s) : EYE103

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Merck & Co

                          Deal Size : $3,000.0 million

                          Deal Type : Acquisition

                          blank

                          03

                          Cophex
                          Not Confirmed
                          Cophex
                          Not Confirmed

                          Details : The proceeds will accelerate the Company’s clinical development program and further build out its innovative retina pipeline, including intravitreal (IVT) Restoret, EYE103 in patients with diabetic macular edema and neovascular age-related macular dege...

                          Product Name : Restoret

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          November 14, 2023

                          Lead Product(s) : EYE103

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Bain Capital Life Sciences

                          Deal Size : $130.0 million

                          Deal Type : Series A Financing

                          blank

                          04

                          Cophex
                          Not Confirmed
                          Cophex
                          Not Confirmed

                          Details : Restoret (EYE103) is a tri-specific Wnt agonist antibody, built based on AntlerA’s ANT-Pharm technology. It is designed to address urgent unmet medical need in patients with back-of-the-eye diseases.

                          Product Name : Restoret

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          June 14, 2023

                          Lead Product(s) : EYE103

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank